10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
9.16
-0.25 (-2.66%)
At close: Mar 28, 2025, 4:00 PM
9.00
-0.16 (-1.75%)
After-hours: Mar 28, 2025, 7:20 PM EDT

10x Genomics Statistics

Total Valuation

10x Genomics has a market cap or net worth of $1.12 billion. The enterprise value is $809.50 million.

Market Cap 1.12B
Enterprise Value 809.50M

Important Dates

The next estimated earnings date is Tuesday, April 29, 2025, after market close.

Earnings Date Apr 29, 2025
Ex-Dividend Date n/a

Share Statistics

10x Genomics has 122.30 million shares outstanding. The number of shares has increased by 2.81% in one year.

Current Share Class 108.25M
Shares Outstanding 122.30M
Shares Change (YoY) +2.81%
Shares Change (QoQ) +0.72%
Owned by Insiders (%) 8.44%
Owned by Institutions (%) 85.34%
Float 106.02M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 1.81
Forward PS 1.81
PB Ratio 1.58
P/TBV Ratio 1.62
P/FCF Ratio n/a
P/OCF Ratio 168.11
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 1.33
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.97, with a Debt / Equity ratio of 0.12.

Current Ratio 4.97
Quick Ratio 4.09
Debt / Equity 0.12
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -48,114.75

Financial Efficiency

Return on equity (ROE) is -25.17% and return on invested capital (ROIC) is -14.77%.

Return on Equity (ROE) -25.17%
Return on Assets (ROA) -12.77%
Return on Invested Capital (ROIC) -14.77%
Return on Capital Employed (ROCE) -24.03%
Revenue Per Employee $467,676
Profits Per Employee -$139,837
Employee Count 1,306
Asset Turnover 0.65
Inventory Turnover 2.50

Taxes

In the past 12 months, 10x Genomics has paid $4.93 million in taxes.

Income Tax 4.93M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -75.39% in the last 52 weeks. The beta is 1.93, so 10x Genomics's price volatility has been higher than the market average.

Beta (5Y) 1.93
52-Week Price Change -75.39%
50-Day Moving Average 12.18
200-Day Moving Average 16.71
Relative Strength Index (RSI) 33.15
Average Volume (20 Days) 3,120,647

Short Selling Information

The latest short interest is 11.32 million, so 9.25% of the outstanding shares have been sold short.

Short Interest 11.32M
Short Previous Month 8.42M
Short % of Shares Out 9.25%
Short % of Float 10.67%
Short Ratio (days to cover) 3.63

Income Statement

In the last 12 months, 10x Genomics had revenue of $610.79 million and -$182.63 million in losses. Loss per share was -$1.52.

Revenue 610.79M
Gross Profit 414.78M
Operating Income -192.46M
Pretax Income -233.22M
Net Income -182.63M
EBITDA -156.58M
EBIT -192.46M
Loss Per Share -$1.52
Full Income Statement

Balance Sheet

The company has $393.40 million in cash and $82.61 million in debt, giving a net cash position of $310.79 million or $2.54 per share.

Cash & Cash Equivalents 393.40M
Total Debt 82.61M
Net Cash 310.79M
Net Cash Per Share $2.54
Equity (Book Value) 710.13M
Book Value Per Share 5.81
Working Capital 466.75M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $6.66 million and capital expenditures -$12.39 million, giving a free cash flow of -$5.73 million.

Operating Cash Flow 6.66M
Capital Expenditures -12.39M
Free Cash Flow -5.73M
FCF Per Share -$0.05
Full Cash Flow Statement

Margins

Gross margin is 67.91%, with operating and profit margins of -31.51% and -29.90%.

Gross Margin 67.91%
Operating Margin -31.51%
Pretax Margin -29.09%
Profit Margin -29.90%
EBITDA Margin -25.64%
EBIT Margin -31.51%
FCF Margin n/a

Dividends & Yields

10x Genomics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -2.80%
Shareholder Yield -2.80%
Earnings Yield -16.30%
FCF Yield -0.51%
Dividend Details

Analyst Forecast

The average price target for 10x Genomics is $20.00, which is 118.34% higher than the current price. The consensus rating is "Buy".

Price Target $20.00
Price Target Difference 118.34%
Analyst Consensus Buy
Analyst Count 16
Revenue Growth Forecast (5Y) 6.71%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

10x Genomics has an Altman Z-Score of 7.44 and a Piotroski F-Score of 5.

Altman Z-Score 7.44
Piotroski F-Score 5